Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review

  • Am J Clin Dermatol. 2025 May;26(3):307-320. doi: 10.1007/s40257-025-00928-w.
Dahyeon Kim  1 ,  Seanna Yang  2 ,  Minka Gill  3 ,  Nickoulet Babaei  1 ,  Mireya Cervantes  4 ,  Jashin J Wu  5
Affiliations
  • 1. Loma Linda University School of Medicine, Loma Linda, CA, USA.
  • 2. Tulane University School of Medicine, New Orleans, LA, USA.
  • 3. Indiana University School of Medicine, Indianapolis, IN, USA.
  • 4. Albany Medical College, Albany, NY, USA.
  • 5. Department of Dermatology, University of Miami Miller School of Medicine, 1600 N.W. 10th Avenue, RMSB, Room 2023-A, Miami, FL, 33136, USA. [email protected].
PMID: 39982633 DOI: 10.1007/s40257-025-00928-w
Abstract

Innovations in biologics are transforming the treatment of psoriatic diseases. The ability to target specific levels of immune activation provides a distinct advantage. Interleukin (IL)-17 inhibitors fall into this class of biologics, and they are effectively used to treat a spectrum of psoriatic diseases, such as psoriasis vulgaris and psoriatic arthritis. In recent years, anti-IL-17 agents have been the focus of therapeutic development, with various formulations and routes of administration. In this manuscript, we review pipeline anti-IL-17 therapies for psoriatic diseases identified through a search of ClinicalTrials.gov (January 2019-December 2024) and Other databases. Key agents under investigation include netakimab, vunakizumab, xeligekimab, gumokimab, HB0017, CJM 112, JS005, 608, LZM012, ZL-1102, izokibep, sonelokimab, DC-806, DC-853, and LEO 153339. Both preclinical and clinical trial data for each agent are summarized, with an emphasis on their efficacy, adverse effects, immunogenicity, and future outlooks.

Products